Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | June 18, 2024
UroGen began the process of a rolling New Drug Application to the FDA for mitomycin as a treatment for patients with NMIBC.
Read More
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | June 6, 2024
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in ...
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | June 6, 2024
Dr. Li details the final results of CORE-001, a phase-2, single arm study of cretostimogene combined with pembrolizumab.
Brandon TwyfordNon-Muscle Invasive Urothelial Carcinoma | May 31, 2024
Urinary tumor DNA predicts residual bladder cancer pre-surgery, improving assessments and treatment, ASCO 2024 study finds
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | May 31, 2024
The CORE-001 trial began in 2020 to study the breakthrough therapy cretostimogene with pembrolizumab for high-risk NMIBC.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | May 28, 2024
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | May 21, 2024
Dr. Li provides commentary on the rationale, design, and impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | May 14, 2024
The primary end point of the analysis of cohort B was 12-month disease-free survival.
Patrick Soon-Shiong, MDNon-Muscle Invasive Urothelial Carcinoma | May 10, 2024
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Vikram M. Narayan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Yair Lotan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | May 3, 2024
Intravesical EMDA/MMC can serve as a safe and effective option for patients with high-risk NMIBC who fail BCG therapy.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | May 3, 2024
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | May 3, 2024
uMRD profiling determines mutations connected with urothelial carcinoma through next-generation sequencing.
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | May 3, 2024
Patients received weekly doses of docetaxel 80 mg, gemcitabine 1000 mg or 2000 mg, and biweekly cisplatin 100 mg.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 23, 2024
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Monika Joshi, MD, MRCPAdvanced Urothelial Carcinoma | May 20, 2024
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 16, 2024
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 15, 2024
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
Advertisement
Advertisement
Advertisement